Sanofi India Ltd
Company Profile
Business description
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
Contact
Saki Vihar Road
Sanofi House, CTS Number 117-B
L&T Business Park
Powai
MumbaiMH400072
INDT: +91 2228032000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
1,104
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,729.10 | 70.30 | -0.80% |
| CAC 40 | 7,981.76 | 5.73 | -0.07% |
| DAX 40 | 24,400.65 | 92.73 | 0.38% |
| Dow JONES (US) | 49,363.88 | 322.24 | -0.65% |
| FTSE 100 | 10,330.55 | 6.80 | 0.07% |
| HKSE | 25,654.20 | 143.65 | -0.56% |
| NASDAQ | 25,870.71 | 220.02 | -0.84% |
| Nikkei 225 | 59,620.71 | 929.88 | -1.54% |
| NZX 50 Index | 12,813.62 | 160.70 | -1.24% |
| S&P 500 | 7,353.61 | 49.44 | -0.67% |
| S&P/ASX 200 | 8,506.60 | 66.50 | -0.78% |
| SSE Composite Index | 4,150.98 | 18.56 | -0.45% |